ISO 10993 & Regulatory
Knowledge Blog
In-depth articles and regulatory update notes on biological evaluation, EU MDR, FDA biocompatibility, CDSCO, and medical device regulatory strategy — written by a practising ISO 10993 consultant.
ISO 10993-1:2025 — The Lifecycle Approach Changes Everything
The 2025 revision of ISO 10993-1 is not just a terminology update. It fundamentally reframes how biological safety must be evaluated across the entire device lifecycle — and many existing BEPs have gaps.
Arvind Rathore
BEP vs BER — The Clearest Distinction You Will Find
These two documents are consistently confused in submissions. Here is the definitive distinction, what each must contain, and the single most common mistake manufacturers make.
Arvind Rathore
CDSCO Biocompatibility Expectations for Medical Devices
What India teams should prepare when biological evaluation is part of the submission pathway, how ISO 10993 fits under MDR 2017, and where otherwise strong files start to look weak.
Arvind Rathore
FDA Biocompatibility Expectations in 2026: What Still Triggers AI Requests
A practical update on what still creates avoidable FDA reviewer friction in biocompatibility files, and what teams should pressure-test before submission.
Arvind Rathore
When ISO 10993-1:2025 Actually Changes the File — and When It Doesn’t
A practical update on where the 2025 revision truly changes BEP and BER work, and when selective remediation is smarter than a full rewrite.
Arvind Rathore
Chemical Characterization Under ISO 10993: What Reviewers Expect
Chemical characterization is no longer supporting data that can sit in the appendix. For many devices, it is the backbone of the chemistry-driven biological safety argument.
Arvind Rathore
5 Reasons FDA Rejects 510(k) Biocompatibility Sections
FDA additional information (AI) requests for biocompatibility are among the most common 510(k) delays. These are the five patterns seen most frequently — and how to avoid every one of them.
Arvind Rathore
FDA AI Responses for Biocompatibility: How to Fix the File
What FDA Additional Information requests on biocompatibility usually mean, how to respond without creating new gaps, and why the best fix often starts in the underlying file.
Arvind Rathore
Can Biological Tests Be Waived? Yes — If Done Correctly
Test waivers are not shortcuts. They are a scientifically rigorous alternative to in vitro or in vivo testing — and ISO 10993-1:2025 actively encourages their use when existing data is sufficient.
Arvind Rathore
EU MDR Annex I §10 — What Notified Bodies Actually Check
Section 10 of Annex I (GSPR) covers chemical, physical, and biological properties. It is one of the most scrutinised sections in EU MDR technical files. Here is what notified bodies look for.
Arvind Rathore
TRA Is Now Central to Modern Biological Evaluation
Toxicological Risk Assessment (TRA) based on chemical characterization has moved from optional supplementary document to a core component of the biological evaluation framework under ISO 10993-1:2025.
Arvind Rathore
Cytotoxicity Testing: What ISO 10993-5 Actually Measures
Cytotoxicity is the most frequently performed biological test for medical devices — but it is also the most misunderstood. What does a “pass” actually mean, and when can it be waived?
Arvind Rathore
ISO 14971 + ISO 10993 Must Work Together
Biological safety is not a standalone compliance checkbox. It is a risk management activity. ISO 10993-1:2025 explicitly requires integration with the ISO 14971 risk management framework.
Arvind Rathore
Material Change? Your Biological Evaluation Needs Re-Assessment
A change to any material in contact with the patient — supplier change, formulation update, coating modification — triggers a structured biological re-evaluation. Here is how to handle it.
Arvind Rathore
ISO 13485 and Biological Evaluation: Where QMS Meets Safety Science
ISO 13485 requires that biological evaluation be managed as a controlled design activity. Understanding how QMS requirements intersect with ISO 10993 documentation prevents the most common audit findings.
Arvind Rathore
Contact Classification: The Foundation of Every Biological Evaluation
Before you can select biological evaluation endpoints, you must correctly classify your device by contact nature and duration. Getting this wrong means your entire evaluation is built on an incorrect foundation.
Arvind Rathore
Scientific Writing for Medical Device Regulatory Submissions
Regulatory documents are scientific documents. They are reviewed by scientists and clinicians who expect precision, clarity, and evidence. The writing standard expected in a BER or CER is closer to a journal article than a technical report.
Arvind Rathore
Get Public Regulatory Updates
LinkedIn is where I share public commentary on ISO 10993, EU MDR, and FDA biocompatibility topics between client projects and longer website articles.